ADE (chemotherapy): Difference between revisions
CSV import |
CSV import |
||
| Line 37: | Line 37: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 03:04, 17 March 2025
ADE (chemotherapy)
ADE is a chemotherapy regimen for treatment of acute myeloid leukemia (AML). It is an acronym for three drugs used in the treatment: Cytarabine (also known as ARA-C), Daunorubicin (also known as Daunomycin), and Etoposide.
Treatment Regimen[edit]
The ADE chemotherapy regimen is typically administered in a hospital setting due to the intensive nature of the treatment. The regimen is usually given in cycles, with each cycle lasting about a week. The specific dosage and schedule may vary depending on the patient's overall health and specific type of AML.
Cytarabine[edit]
Cytarabine, or ARA-C, is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. It is given by injection into a vein or under the skin.
Daunorubicin[edit]
Daunorubicin, or Daunomycin, is a chemotherapy drug that works by stopping the growth of cancer cells. It is given by injection into a vein.
Etoposide[edit]
Etoposide is a chemotherapy drug that works by stopping the growth of cancer cells. It is given by injection into a vein.
Side Effects[edit]
Like all chemotherapy regimens, ADE can cause side effects. These may include nausea, vomiting, hair loss, and fatigue. More serious side effects can include infection, bleeding, and anemia. Patients should discuss potential side effects with their healthcare provider before starting treatment.
